Levosimendan vs. intra-aortic balloon pump in high-risk cardiac surgery

Asian Cardiovascular and Thoracic Annals

Volumn 19, Issue 2, 2011, Pages 154-159

  Lomivorotov, Vladimir V ^a   Cherniavskiy, Alexander M ^a   Boboshko, Vladimir A ^a   Kornilov, Igor A ^a   Lomivorotov, Vladimir N ^a   Karaskov, Alexander M ^a  

^a MESHALKIN NATIONAL MEDICAL RESEARCH CENTER   (Russian Federation)

Author keywords

Cardiopulmonary bypass; Coronary artery bypass grafting; Heart failure; Intra aortic balloon pump; Levosimendan substance name

Indexed keywords

LEVOSIMENDAN; TROPONIN I;

ADULT; AORTA BALLOON; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; FEMALE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEART SURGERY; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; MALE; POSTOPERATIVE COMPLICATION;

AGED; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; HEART DISEASES; HEMODYNAMICS; HUMANS; HYDRAZONES; INTRA-AORTIC BALLOON PUMPING; MALE; MIDDLE AGED; PYRIDAZINES; RISK ASSESSMENT; RISK FACTORS; RUSSIA; STROKE VOLUME; TREATMENT OUTCOME; TROPONIN I; VENTRICULAR FUNCTION, LEFT;

EID: 79955984961     PISSN: 02184923     EISSN: 02184923     Source Type: Journal    
DOI: 10.1177/0218492311401143     Document Type: Article

References (19)

1. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Cicrulation 2001;104:2996-3007. (Pubitemid 33139116)
2. Adams Jr KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-216. (Pubitemid 40348525)
3. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Rydén L, et al. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003;89:42-48. (Pubitemid 36044288)
4. O'Connor CM, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, et al. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). Am J Cardiol 2002;90:101-107. (Pubitemid 34775115)
5. Caparrelli DJ, Ghazoul M and Diethrich EB. Indications for coronary artery bypass grafting in 2009: what is left to surgery. J Cardiovasc Surg (Torino) 2009;50:19-28.
6. Chernov SA. Early postoperative complications and prevention of them in ischemic heart disease patients after direct myocardial revascularization. Ter Arkh 2002;74:45-49.
7. Lorusso R, Gelsomino S, Carella R, Livi U, Mariscalco G, Onorati F, et al. Impact of prophylactic intra-aortic balloon counter-pulsation on postoperative outcome in highrisk cardiac surgery patients: a multicentre, propensity-score analysis. Eur J Cardiothorac Surg 2010;38:585-591.
8. Meharwal ZS and Trehan N. Vascular complications of intra-aortic balloon insertion in patients undergoing coronary revascularization: analysis of 911 cases. Eur J Cardiothorac Surg 2002;21:741-747. (Pubitemid 34257962)
9. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-668. (Pubitemid 28224690)
10. Kersten JR, Montgomery MW, Pagel PS and Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K (ATP) channels. Anesth Analg 2000;90:5-11. (Pubitemid 30022959)
11. Kolseth SM, Nordhaug DO, Stenseth R, Sellevold O, Kirkeby-Garstad I and Wahba A. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function. Eur J Cardiothorac Surg 2009;36:1024-1030.
12. Lavana JD, Fraser JF, Smith SE, Drake L, Tesar P and Mullany DV. Influence of timing of intra-aortic balloon placement in cardiac surgical patients. J Thorac Cardiovasc Surg 2010;140:80-85.
13. Cohen M, Urban P, Christenson JT, Joseph DL, Freedman Jr RJ, Miller MF, et al. Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry. Eur Heart J 2003;24:1763-1770. (Pubitemid 37236866)
14. Landoni G, Mizzi A, Biondi-Zoccai G, Bignami E, Prati P and Ajello V. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol 2010;76:276-286.
15. Takeda S, Nakanishi K, Ikezaki H, Kim C, Sakamoto A, Tanaka K, et al. Cardiac marker responses to coronary artery bypass graft surgery with cardiopulmonary bypass and aortic cross-clamping. J Cardiothorac Vasc Anesth 2002;16:421-425. (Pubitemid 34839696)
16. Lurati Buse GA, Koller MT, Grapow M, Bolliger D, Seeberger M and Filipovic M. The prognostic value of troponin release after adult cardiac surgery-a metaanalysis. Eur J Cardiothorac Surg 2010;37:399-406.
17. Das B and Sarkar C. Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model. Vascul Pharmacol 2007;47:248-256. (Pubitemid 47470049)
18. du Toit EF, Genis A, Opie LH, Pollesello P and Lochner A. A role for the RISK pathway and K (ATP) channels in pre-and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 2008;154:41-50. (Pubitemid 351620393)
19. Hönisch A, Theuring N, Ebner B, Wagner C, Strasser RH and Weinbrenner C. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol 2010;105:155-167.